CO6331435A2 - Nuevas formas polimórficas de dihidróheno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-3{-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparación - Google Patents

Nuevas formas polimórficas de dihidróheno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-3{-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparación

Info

Publication number
CO6331435A2
CO6331435A2 CO11078454A CO11078454A CO6331435A2 CO 6331435 A2 CO6331435 A2 CO 6331435A2 CO 11078454 A CO11078454 A CO 11078454A CO 11078454 A CO11078454 A CO 11078454A CO 6331435 A2 CO6331435 A2 CO 6331435A2
Authority
CO
Colombia
Prior art keywords
piridazin
etoxi
morfolin
bencil
pirimidin
Prior art date
Application number
CO11078454A
Other languages
English (en)
Inventor
Axel Becker
Clemens Huehn
Christoph Saal
Oliver Schadt
Dieter Dorsch
Eva Kriegbaum
Frank Stieber
Christina Donini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41609799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6331435(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CO6331435A2 publication Critical patent/CO6331435A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención de refiere a DIHIDRÓGENO-FOSFATO DE 6-(1-METIL-1H-PIRAZOL-4-IL)-2-{3-{5-(2-MORFOLIN-4-IL-ETOXI)-PIRIMIDIN-2-IL]-BENCIL}-2H-PIRIDAZIN-3-ONA, sus solvatos y modificaciones cristalinas. La presente invención también se refiere a procesos de preparación de estas modificaciones cristalinas, así como a su uso en el tratamiento y/o la prevención de condiciones fisiológicas y/o patofisiológicas que son causadas, mediadas y/o propagadas por la inhibición, regulación y/o modulación de la transducción de señales de quinasas, en particular por la inhibición de tirosina quinasas, por ejemplo, condiciones patofisiológicas como el cáncer
CO11078454A 2008-12-22 2011-06-22 Nuevas formas polimórficas de dihidróheno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-3{-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparación CO6331435A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08022253 2008-12-22

Publications (1)

Publication Number Publication Date
CO6331435A2 true CO6331435A2 (es) 2011-10-20

Family

ID=41609799

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11078454A CO6331435A2 (es) 2008-12-22 2011-06-22 Nuevas formas polimórficas de dihidróheno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-3{-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparación

Country Status (32)

Country Link
US (1) US8586599B2 (es)
EP (1) EP2361250B1 (es)
JP (2) JP5690741B2 (es)
KR (1) KR101663335B1 (es)
CN (1) CN102264729B (es)
AR (1) AR074686A1 (es)
AU (1) AU2009331990B2 (es)
BR (1) BRPI0923480B8 (es)
CA (1) CA2748218C (es)
CL (1) CL2011001278A1 (es)
CO (1) CO6331435A2 (es)
CY (1) CY1114659T1 (es)
DK (1) DK2361250T3 (es)
EA (1) EA019320B1 (es)
EC (1) ECSP11011219A (es)
ES (1) ES2434247T3 (es)
HK (1) HK1164837A1 (es)
HR (1) HRP20130993T1 (es)
IL (1) IL213647A (es)
MX (1) MX2011006682A (es)
MY (1) MY160526A (es)
NZ (1) NZ594172A (es)
PE (1) PE20120016A1 (es)
PL (1) PL2361250T3 (es)
PT (1) PT2361250E (es)
SG (1) SG172128A1 (es)
SI (1) SI2361250T1 (es)
SM (1) SMT201300133B (es)
TW (1) TWI448463B (es)
UA (1) UA103646C2 (es)
WO (1) WO2010072295A1 (es)
ZA (1) ZA201105394B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
TWI797176B (zh) 2017-10-17 2023-04-01 西班牙商帕羅製藥有限公司 ４-胺基嘧啶化合物之合成

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
MXPA04003668A (es) 2001-10-31 2004-07-22 Merck Patent Gmbh Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
AU2003297431A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
MXPA06000091A (es) 2003-07-02 2006-04-07 Sugen Inc Arilmetiltriazolo e imidazopirazinas como inhibidores de c-met.
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
AU2006320580B2 (en) 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
BRPI0620292B1 (pt) 2005-12-21 2021-08-24 Janssen Pharmaceutica N. V. Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
TW200922584A (en) 2007-10-16 2009-06-01 Novartis Ag Organic compounds
MX2010004491A (es) 2007-10-25 2010-06-21 Astrazeneca Ab Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares.
AU2008319735A1 (en) 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone derivatives and use thereof as P2X7 receptor inhibitors
CL2008003407A1 (es) 2007-11-16 2010-01-11 Boehringer Ingelheim Int Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
EP2072506A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
CA2705411A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
PE20091669A1 (es) 2007-12-21 2009-12-06 Exelixis Inc Benzofuropirimidinonas
CL2008003799A1 (es) 2007-12-21 2009-12-18 Synthon Bv Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
BRPI0821349A2 (pt) 2007-12-21 2019-09-24 Hoffmann La Roche compostos antivirais heterocíclicos
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8003649B2 (en) 2007-12-21 2011-08-23 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155
AR069814A1 (es) 2007-12-21 2010-02-17 Palau Pharma Sa Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
JP5390610B2 (ja) 2008-07-25 2014-01-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成
US20120028988A1 (en) 2009-03-30 2012-02-02 Sumitomo Chemical Company, Limited Use of pyridazinone compound for control of harmful arthropod pests
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
DK2361250T3 (da) 2013-11-04
IL213647A (en) 2013-11-28
BRPI0923480A2 (pt) 2016-08-09
EA019320B1 (ru) 2014-02-28
ZA201105394B (en) 2012-03-28
EP2361250B1 (en) 2013-08-07
KR101663335B1 (ko) 2016-10-06
WO2010072295A1 (en) 2010-07-01
CA2748218A1 (en) 2010-07-01
JP2012513417A (ja) 2012-06-14
US20110257180A1 (en) 2011-10-20
AU2009331990A1 (en) 2011-08-11
PE20120016A1 (es) 2012-01-24
MX2011006682A (es) 2011-07-13
CL2011001278A1 (es) 2011-09-30
CN102264729B (zh) 2014-03-05
SI2361250T1 (sl) 2013-12-31
SMT201300133B (it) 2014-03-07
BRPI0923480B1 (pt) 2020-10-13
US8586599B2 (en) 2013-11-19
AR074686A1 (es) 2011-02-02
SG172128A1 (en) 2011-07-28
PL2361250T3 (pl) 2014-01-31
EP2361250A1 (en) 2011-08-31
BRPI0923480B8 (pt) 2021-05-25
AU2009331990B2 (en) 2016-04-14
JP5690741B2 (ja) 2015-03-25
HK1164837A1 (en) 2012-09-28
UA103646C2 (ru) 2013-11-11
JP2015028093A (ja) 2015-02-12
NZ594172A (en) 2013-04-26
IL213647A0 (en) 2011-07-31
JP5860125B2 (ja) 2016-02-16
CA2748218C (en) 2017-08-29
ES2434247T3 (es) 2013-12-16
CN102264729A (zh) 2011-11-30
ECSP11011219A (es) 2011-12-30
CY1114659T1 (el) 2016-10-05
TW201028409A (en) 2010-08-01
TWI448463B (zh) 2014-08-11
MY160526A (en) 2017-03-15
HRP20130993T1 (hr) 2013-11-22
EA201100973A1 (ru) 2012-01-30
KR20110089462A (ko) 2011-08-08
PT2361250E (pt) 2013-11-11

Similar Documents

Publication Publication Date Title
ECSP11011248A (es) Nuevas formas polimórficas de sal de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo y sus procesos de preparación.
ECSP11011534A (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- o heptano-nitrilo como inhibidores de jak
CU24187B1 (es) Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis
HN2010001761A (es) Derivados de azetidina y ciclobutano como inhibidores de jak
CO6612243A2 (es) Derivados de [1.8]naftiridina
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
NI201200061A (es) Derivados de quinazolina-4(3h)-ona utilizados como inhibidores de la cinasa de pi3
CL2012003503A1 (es) Compuestos derivados de morfolin pirimidinas sustituidos, inhibidores de la proteina quinasa atr; composicion farmaceutica, utiles para la prevencion o el tratamiento de tumores cancerigenos.
SV2010003463A (es) Compuestos organicos
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
GT201300046A (es) Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3)
CO6640285A2 (es) 5-alquinil-pirimidinas
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
ECSP088791A (es) Compuestos pirazólicos heterobicíclicos y métodos de uso.
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.
UY32529A (es) Compuestos heterocíclicos y su uso como inhibidores de la glucógeno sintetasa quinasa 3
WO2014194245A3 (en) Cdk8 inhibitors and uses thereof
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
CO6331435A2 (es) Nuevas formas polimórficas de dihidróheno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-3{-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparación
CL2009001112A1 (es) Compuestos derivados de cinolin-3-carboxamida, inhibidores de la quinasa csf-1r; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
DOP2009000218A (es) Proceso e intermediarios para preparar arzoxifeno

Legal Events

Date Code Title Description
FG Application granted